Document is current
Any future updates will be listed below
-
Authors
Vermij, Lisa https://orcid.org/0000-0003-4687-5550
Jobsen, Jan J. https://orcid.org/0000-0001-7663-0170
León-Castillo, Alicia
Brinkhuis, Mariel
Roothaan, Suzan
Powell, Melanie E.
de Boer, Stephanie M.
Khaw, Pearly
Mileshkin, Linda R.
Fyles, Anthony
Leary, Alexandra
Genestie, Catherine
Jürgenliemk-Schulz, Ina M.
Crosbie, Emma J. https://orcid.org/0000-0003-0284-8630
Mackay, Helen J.
Nijman, Hans. W. https://orcid.org/0000-0002-1821-3042
Nout, Remi A.
Smit, Vincent T. H. B. M.
Creutzberg, Carien L. https://orcid.org/0000-0002-7008-4321
Horeweg, Nanda
Bosse, Tjalling https://orcid.org/0000-0002-6881-8437
,
de Boer, Stephanie M.
-
Funding
Funding for this research was provided by:
DH | National Institute for Health Research (IS-BRC-1215-20007)
KWF Kankerbestrijding (UL2006-4168/CKTO 2006-04, 31843)
- License Information
-
More Information
Article History
Received: 6 September 2022
Revised: 20 December 2022
Accepted: 4 January 2023
First Online: 23 January 2023
Competing interests
: The authors declare no competing interests.
: The PORTEC-3 randomised clinical trial was approved by the ethics committees at all participating centres. Written informed consent was obtained from all patients. Translational study of the MST cohort was approved by the Leiden-Den Haag-Delft medical ethics committee, and a waiver for informed consent for the MST cohort was given. The study was performed in accordance with the Declaration of Helsinki.
